The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | EPCORE NHL-2: epcoritamab + intensive chemotherapy in patients with R/R DLBCL eligible for autoSCT
Marek Trněný, MD, Charles University Hospital, Prague, Czech Republic, discusses findings from the EPCORE NHL-2 trial (NCT04663347) evaluating epcoritamab in combination with intensive chemotherapy for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who failed first-line treatment and are eligible for high-dose therapy or autologous stem cell transplant (autoSCT). The study reported a response rate of 80% and a complete remission rate of 60%, highlighting the potential of this approach to improve transplant eligibility and serve as an effective bridge to CAR T-cell therapy or further treatment. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
